US4436753A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for therapy of ischemic disease
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1980-12-17
•
Granted: 1984-03-13
•
Expires: 2000-12-17
Abstract
Abstract A mammal suffering from ischemic disease such as cerebral apoplexy, cardiac insufficiency, renal insufficiency due to vascular changes, etc. is remedied by administering to said mammal an effective amount of a compound of the formula: ##STR1## wherein n is an integer of from 4 to 22.
Inventors
- 👤 Isuke Imada
- 👤 Akinobu Nagaoka
- 👤 Minoru Hirata
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 01:25
CPC Classifications
C; C07; C07C; C07C43/00; C07C43/02; C07C43/20; C07C43/23; A; A61; A61P; A61P25/00; A61P25/28; A61P43/00; C07C45/00; C07C45/61; C07C45/67; C07C45/673; C07C46/00; C07C46/02; C07C46/06; C07C46/08; C07C50/00; C07C50/26; C07C50/28
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
79 words
A method of improving cellular metabolism in the treatment of ischemic diseases comprising cerebral infarction, cerebral hemorrhage, cerebral hemorrhagic infarction, cerebral embolus, cardiac failure, nephrosclerosis, proteinuria due to vascular lesion and renovascular hypertension, which comprises administering to a mammal suffering from the disease a compound of the formula: ##STR6## wherein n is an integer of from 4 to 22, in an amount of about 0.006 mg to 12 mg per kilogram of body weight of the mammal per day.
Claim 2
Independent Claim
79 words
A method of improving cellular metabolism in the treatment of ischemic diseases comprising cerebral infarction, cerebral hemorrhage, cerebral hemorrhagic infarction, cerebral embolus, cardiac failure, nephrosclerosis, proteinuria due to vascular lesion and renovascular hypertension, which comprises administering to a mammal suffering from the disease a compound of the formula: ##STR6## wherein n is an integer of from 4 to 22, in an amount of about 0.006 mg to 12 mg per kilogram of body weight of the mammal per day.
Claim 3
Dependent Claim
33 words
A method as claimed in claim 1, wherein the compound is administered orally in an amount of about 0.1 mg to 12 mg per kilogram of body weight of the mammal per day.
Claim 4
Dependent Claim
33 words
A method as claimed in claim 1, wherein the compound is administered intravenously in an amount of about 0.006 mg to 2 mg per kilogram of body weight of the mammal per day.
Claim 5
Dependent Claim
20 words
A method as claimed in claim 1, wherein n in the formula is an integer of from 6 to 18.
Claim 6
Dependent Claim
12 words
A method as claimed in claim 1, wherein the compound is 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone.
Claim 7
Dependent Claim
12 words
A method as claimed in claim 1, wherein the compound is 2,3-dimethoxy-5-methyl-6-(11-hydroxyundecyl)-1,4-benzoquinone.
Claim 8
Dependent Claim
12 words
A method as claimed in claim 1, wherein the compound is 2,3-dimethoxy-5-methyl-6-(12-hydroxydodecyl)-1,4-benzoquinone.
Claim 9
Dependent Claim
12 words
A method as claimed in claim 1, wherein the compound is 2,3-dimethoxy-5-methyl-6-(13-hydroxytridecyl)-1,4-benzoquinone.
References Cited (Backward Citations)
US4139545A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-13 | 1987-09-12 | 1988-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-13 | 1991-09-12 | 1992-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-13 | 1995-09-12 | 1996-03-13 | $7700.00 | Window Closed / Lapsed |